drugset / Trial / NCT00481572

Continuous Infusion of Terlipressin in Septic Shock

NCT00481572

Phase 2 Completed 45 enrolled University of Roma La Sapienza
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether: A)the continuous infusion ultra-low dose of terlipressin (1.3 micrograms/kg/h) is able to stabilize hemodynamic in patients with septic shock, reducing the risk of adverse effects related to the bolus dose.B)the continuous infusion ultra-low dose of terlipressin may be use in lieu of vasopressin.

Timeline

Start
2007-01
Primary completion
2007-12
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Norepinephrine Other / unclassified 15 ug
Subject Terlipressin Peptide 1.3 ug/kg
Subject Vasopressin Peptide 0.03 iu Intravenous